MedImaging

Download Mobile App
Recent News Radiography MRI Ultrasound Nuclear Medicine General/Advanced Imaging Imaging IT Industry News

MRI Guides Surgical Decision-Making for Lateral Pelvic Lymph Node Metastases in Rectal Cancer

By MedImaging International staff writers
Posted on 28 Jul 2022
Print article
Image: LPLN metastases are an important cause of preventable local failure in rectal cancer (Photo courtesy of Pexels)
Image: LPLN metastases are an important cause of preventable local failure in rectal cancer (Photo courtesy of Pexels)

Lateral pelvic lymph node (LPLN) metastasis is an important clinical problem in rectal cancer, and there is no global consensus on how to treat it. In Western countries, locally advanced rectal cancer is typically treated with total neoadjuvant therapy (TNT) and total mesorectal excision (TME). LPLN dissection (LPLND) traditionally has been performed in Eastern countries but has not been widely adopted in the West due to concerns about potential morbidity and technical difficulty. Now, a new study has evaluated clinical and oncological outcomes following magnetic resonance imaging (MRI)-directed surgical selection for LPLND after TNT.

The retrospective single-institution study by researchers at The University of Texas MD Anderson Cancer Center (Houston, TX, USA) examined outcomes when MRI was used to facilitate appropriate selection of patients requiring additional surgery, or LPLND, following TNT. A retrospective consecutive cohort analysis was performed of rectal cancer patients with enlarged LPLN on pre-treatment MRI. Patients were categorized as LPLND or non-LPLND. The main outcomes were lateral local recurrence rate, perioperative and oncological outcomes and factors associated with decision-making for LPLND.

The study identified 158 patients with enlarged pre-treatment LPLNs who received TNT; 88 patients (56.0%) underwent LPLND, after MRI assessment by a multidisciplinary team. The MD Anderson team reported good outcomes for LPLND with major morbidity (19.3% vs. 17%) and recurrence rates (3.4% vs. 4.6%) that did not differ between the patients who did and did not receive LPLND, indicating that MRI can be used to select patients for LPLND.

Based on these findings, the researchers concluded that for rectal cancer patients with evidence of LPLN metastasis, the appropriate selection of patients for LPLND can be facilitated by a multidisciplinary MRI directed approach with no significant difference in perioperative or oncologic outcomes.

Related Links:
The University of Texas MD Anderson Cancer Center 

Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
New
Ceiling-Mounted Digital Radiography System
Radiography 5000 C
PACS Workstation
CHILI Web Viewer
New
Wireless Handheld Ultrasound System
TE Air

Print article

Channels

Ultrasound

view channel
Image: CAM figures of testing images (Photo courtesy of SPJ; DOI:10.34133/research.0319)

Diagnostic System Automatically Analyzes TTE Images to Identify Congenital Heart Disease

Congenital heart disease (CHD) is one of the most prevalent congenital anomalies worldwide, presenting substantial health and financial challenges for affected patients. Early detection and treatment of... Read more

Nuclear Medicine

view channel
Image: Researchers have identified a new imaging biomarker for tumor responses to ICB therapy (Photo courtesy of 123RF)

New PET Biomarker Predicts Success of Immune Checkpoint Blockade Therapy

Immunotherapies, such as immune checkpoint blockade (ICB), have shown promising clinical results in treating melanoma, non-small cell lung cancer, and other tumor types. However, the effectiveness of these... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more